secwatch / observer
8-K filed June 2, 2023, 7:59 PM ET ticker ELTX CIK 0001601485
M&A confidence high sentiment neutral materiality 0.90

Elicio Therapeutics, Inc. (ELTX): auditor change — Angion completes merger with Elicio, becomes Elicio Therapeutics; ticker changes to ELTX

Elicio Therapeutics, Inc.

item 2.01item 3.03item 4.01item 5.01item 5.02item 5.03item 5.07item 7.01item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Annette Matthies

Chief Business Officer
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
Annette Matthies, Ph.D. 46 Chief Business Officer
Appointed

Yekaterina (Katie) Chudnovsky

Class I Director
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
Yekaterina (Katie) Chudnovsky 38 Class I Director
Appointed

Brian Piekos

Chief Financial Officer
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
Brian Piekos 48 Chief Financial Officer
Departed

Gregory S. Curhan

Chief Financial Officer
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Successor
Brian Piekos
Filed
June 2, 2023, 7:59 PM ET
(ii) each of Gregory S. Curhan, Angion’s Chief Financial Officer and Jay R. Venkatesan, M.D., were terminated as employees of the Company effective as of the effective time of the Merger.
Departed

Jay R. Venkatesan

Other
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
(ii) each of Gregory S. Curhan, Angion’s Chief Financial Officer and Jay R. Venkatesan, M.D., were terminated as employees of the Company effective as of the effective time of the Merger.
Appointed

Christopher Haqq

Executive Vice President, Head of Research and Development and Chief Medical Officer
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
Christopher Haqq, M.D., Ph.D. 57 Executive Vice President, Head of Research and Development and Chief Medical Officer
Appointed

Julian Adams

Chair of the Board and Class III Director
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
Julian Adams, Ph.D. 68 Chair of the Board and Class III Director
Departed

Victor F. Ganzi

director (resigned)
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
each of Victor F. Ganzi, J.D., Itzhak D. Goldberg, M.D. and Gilbert S. Omenn, M.D., Ph.D., resigned from Angion’s board of directors and any respective committee membership of Angion’s board of directors, effective as of the effective time of Merger
Departed

Itzhak D. Goldberg

director (resigned)
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
each of Victor F. Ganzi, J.D., Itzhak D. Goldberg, M.D. and Gilbert S. Omenn, M.D., Ph.D., resigned from Angion’s board of directors and any respective committee membership of Angion’s board of directors, effective as of the effective time of Merger
Appointed

Robert R. Ruffolo, Jr.

Class II Director
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
Robert R. Ruffolo, Jr., Ph.D., FCPP 73 Class II Director
Role change

Ms. Rhodes

Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
Ms. Rhodes, the former Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary, will step down from each such respective role, but will continue to be employed by the Company for a period of 30 days.
Appointed

Robert Connelly

Chief Executive Officer, President and Class I Director
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
Robert Connelly 63 Chief Executive Officer, President and Class I Director
Appointed

Assaf Segal

Class II Director
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
Assaf Segal 51 Class II Director
Appointed

Peter DeMuth

Chief Scientific Officer
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
Peter DeMuth, Ph.D. 37 Chief Scientific Officer
Departed

Gilbert S. Omenn

director (resigned)
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
each of Victor F. Ganzi, J.D., Itzhak D. Goldberg, M.D. and Gilbert S. Omenn, M.D., Ph.D., resigned from Angion’s board of directors and any respective committee membership of Angion’s board of directors, effective as of the effective time of Merger
Appointed

Carol Ashe

Class III Director
ELTX · Elicio Therapeutics, Inc.
Effective
2023-06-01
Filed
June 2, 2023, 7:59 PM ET
Carol Ashe 65 Class III Director

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Elicio Therapeutics, Inc. dismissed Moss Adams LLP as its auditor.

Action
dismissal
Auditor
Moss Adams LLP
Successor
Baker Tilly US, LLP
Exact text from the filing
(a) On June 1, 2023, the Audit Committee (the “Audit Committee”) of the board of directors of the Company approved the dismissal of Moss Adams LLP (“Moss Adams”) as the Company’s independent registered public accounting firm, effective immediately.
View on SEC.gov
Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Elicio Therapeutics, Inc. engaged Baker Tilly US, LLP as its auditor.

Action
engagement
Auditor
Baker Tilly US, LLP
Exact text from the filing
(b) On June 1, 2023, the Audit Committee approved, on behalf of the Company, the engagement of Baker Tilly US, LLP (“Baker Tilly”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Annette Matthies was appointed as Chief Business Officer at Elicio Therapeutics, Inc..

Action
appointed
Role
Chief Business Officer
Exact text from the filing
Annette Matthies, Ph.D. 46 Chief Business Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Yekaterina (Katie) Chudnovsky was appointed as Class I Director at Elicio Therapeutics, Inc..

Action
appointed
Role
Class I Director
Exact text from the filing
Yekaterina (Katie) Chudnovsky 38 Class I Director
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Piekos was appointed as Chief Financial Officer at Elicio Therapeutics, Inc..

Action
appointed
Role
Chief Financial Officer
Exact text from the filing
Brian Piekos 48 Chief Financial Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Gregory S. Curhan was terminated as Chief Financial Officer at Elicio Therapeutics, Inc..

Action
terminated
Role
Chief Financial Officer
Exact text from the filing
(ii) each of Gregory S. Curhan, Angion’s Chief Financial Officer and Jay R. Venkatesan, M.D., were terminated as employees of the Company effective as of the effective time of the Merger.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jay R. Venkatesan was terminated as other at Elicio Therapeutics, Inc..

Action
terminated
Exact text from the filing
(ii) each of Gregory S. Curhan, Angion’s Chief Financial Officer and Jay R. Venkatesan, M.D., were terminated as employees of the Company effective as of the effective time of the Merger.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Haqq was appointed as Executive Vice President, Head of Research and Development and Chief Medical Officer at Elicio Therapeutics, Inc..

Action
appointed
Role
Executive Vice President, Head of Research and Development and Chief Medical Officer
Exact text from the filing
Christopher Haqq, M.D., Ph.D. 57 Executive Vice President, Head of Research and Development and Chief Medical Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Julian Adams was appointed as Chair of the Board and Class III Director at Elicio Therapeutics, Inc..

Action
appointed
Role
Chair of the Board and Class III Director
Exact text from the filing
Julian Adams, Ph.D. 68 Chair of the Board and Class III Director
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Victor F. Ganzi resigned as director (resigned) at Elicio Therapeutics, Inc..

Action
resigned
Role
director (resigned)
Exact text from the filing
each of Victor F. Ganzi, J.D., Itzhak D. Goldberg, M.D. and Gilbert S. Omenn, M.D., Ph.D., resigned from Angion’s board of directors and any respective committee membership of Angion’s board of directors, effective as of the effective time of Merger
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Itzhak D. Goldberg resigned as director (resigned) at Elicio Therapeutics, Inc..

Action
resigned
Role
director (resigned)
Exact text from the filing
each of Victor F. Ganzi, J.D., Itzhak D. Goldberg, M.D. and Gilbert S. Omenn, M.D., Ph.D., resigned from Angion’s board of directors and any respective committee membership of Angion’s board of directors, effective as of the effective time of Merger
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert R. Ruffolo, Jr. was appointed as Class II Director at Elicio Therapeutics, Inc..

Action
appointed
Role
Class II Director
Exact text from the filing
Robert R. Ruffolo, Jr., Ph.D., FCPP 73 Class II Director
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Ms. Rhodes changed role as Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary at Elicio Therapeutics, Inc..

Action
stepped down
Role
Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary
Exact text from the filing
Ms. Rhodes, the former Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary, will step down from each such respective role, but will continue to be employed by the Company for a period of 30 days.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Connelly was appointed as Chief Executive Officer, President and Class I Director at Elicio Therapeutics, Inc..

Action
appointed
Role
Chief Executive Officer, President and Class I Director
Exact text from the filing
Robert Connelly 63 Chief Executive Officer, President and Class I Director
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Assaf Segal was appointed as Class II Director at Elicio Therapeutics, Inc..

Action
appointed
Role
Class II Director
Exact text from the filing
Assaf Segal 51 Class II Director
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Peter DeMuth was appointed as Chief Scientific Officer at Elicio Therapeutics, Inc..

Action
appointed
Role
Chief Scientific Officer
Exact text from the filing
Peter DeMuth, Ph.D. 37 Chief Scientific Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Gilbert S. Omenn resigned as director (resigned) at Elicio Therapeutics, Inc..

Action
resigned
Role
director (resigned)
Exact text from the filing
each of Victor F. Ganzi, J.D., Itzhak D. Goldberg, M.D. and Gilbert S. Omenn, M.D., Ph.D., resigned from Angion’s board of directors and any respective committee membership of Angion’s board of directors, effective as of the effective time of Merger
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Carol Ashe was appointed as Class III Director at Elicio Therapeutics, Inc..

Action
appointed
Role
Class III Director
Exact text from the filing
Carol Ashe 65 Class III Director
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Elicio Therapeutics, Inc.: Name change amendment from Angion Biomedica Corp. to Elicio Therapeutics, Inc (effective 2023-06-01).

Change
charter amendment
Effective
2023-06-01
Exact text from the filing
Immediately prior to the consummation of the Merger, on June 1, 2023, Angion filed the Name Change Amendment changing its name from “Angion Biomedica Corp.” to “Elicio Therapeutics, Inc.”
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Elicio Therapeutics, Inc. underwent a change of control involving Elicio Therapeutics, Inc. (closed 2023-06-01).

Action
change of control
Counterparty
Elicio Therapeutics, Inc.
Closing
2023-06-01
Exact text from the filing
On June 1, 2023, the Delaware corporation formerly known as "Angion Biomedica Corp." completed its previously announced merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of January 17, 2023 (the "Merger Agreement"), by and among Angion Biomedica Corp. ("Angion"), Arkham Merger Sub, Inc., a wholly owned subsidiary of Angion ("Merger Sub"), and Elicio Therapeutics, Inc. ("Elicio"), pursuant to which Merger Sub merged with and into Elicio, with Elicio surviving the merger as a wholly owned subsidiary of Angion (the "Merger").
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Elicio Therapeutics, Inc. shareholders approved To approve an amendment to the amended and restated certificate of incorporation of Angion to effect a reverse stock split of Angion common stock at a ratio within the range between 5-for-1 to 30-for-1 at the 2023-05-31 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2023-05-31
Exact text from the filing
Proposal 2. To approve an amendment to the amended and restated certificate of incorporation of Angion to effect a reverse stock split of Angion common stock at a ratio within the range between 5-for-1 to 30-for-1: 22,792,786 For 449,015 Against 1,185,607 Abstain 0 Broker Non-Votes
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Elicio Therapeutics, Inc. shareholders approved To approve the issuance of shares of Angion capital stock pursuant to the Merger, which will represent more than 20% of the shares of Angion common stock outstanding immediately prior to the Merger and result in a change of control of Angion, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b) at the 2023-05-31 meeting.

Proposal
merger approval
Outcome
passed
Meeting
2023-05-31
Exact text from the filing
Proposal 1. To approve the issuance of shares of Angion capital stock pursuant to the Merger, which will represent more than 20% of the shares of Angion common stock outstanding immediately prior to the Merger and result in a change of control of Angion, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b): 17,841,302 For 1,109,168 Against 74,010 Abstain 5,402,928 Broker Non-Votes
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Elicio Therapeutics, Inc. shareholders approved To approve an amendment to the Angion amended and restated certificate of incorporation of Angion to provide for the exculpation of officers at the 2023-05-31 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2023-05-31
Exact text from the filing
Proposal 3. To approve an amendment to the Angion amended and restated certificate of incorporation of Angion to provide for the exculpation of officers: 17,192,853 For 248,833 Against 1,582,794 Abstain 5,402,928 Broker Non-Votes
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

Elicio Therapeutics, Inc. shareholders approved To elect the Angion Board nominees, Itzhak Goldberg, M.D., F.A.C.R. and Allen R. Nissenson, M.D., to the Angion Board in the class of directors to hold office until the 2026 Annual Meeting of Stockholders at the 2023-05-31 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-05-31
Exact text from the filing
Proposal 4. To elect the Angion Board nominees, Itzhak Goldberg, M.D., F.A.C.R. and Allen R. Nissenson, M.D., to the Angion Board in the class of directors to hold office until the 2026 Annual Meeting of Stockholders: Name Votes For Votes Withheld Broker Non-Votes Itzhak Goldberg, M.D., F.A.C.R. 18,180,899 843,581 5,402,928 Allen R. Nissenson, M.D. 18,214,543 809,937 5,402,928
View on SEC.gov

46 auditor changes filed in the last 30 days. Browse all auditor changes →

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001140361-23-028077
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.